Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Bevacizumab with Stereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma
KCT0010616Phase 2Recruiting
- Sponsor
- Yongin Severance Hospital
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Yongin Severance Hospital. Started May 2024; status: recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on KCT0010616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010616.